The review found no eligible studies for this question.
ACUTE: Serelaxin showed no clear difference in hypotension compared with placebo (low certainty).
It is very uncertain whether surgical reimplantation of ureters plus antibiotics changes hypertension compared with antibiotics alone (very low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
Low dialysate [Na+] (< 138 mM) showed no clear difference in intradialytic hypotension compared with high dialysate [Na+] (> 140 mM) (low certainty).
The review found no eligible studies for this question.
Low dialysate [Na+] (< 138 mM) probably leads to higher intradialytic hypotension compared with neutral dialysate [Na+] (138 to 140 mM) or high dialysate [Na+] (>… (moderate certainty).
Low dialysate [Na+] (< 138 mM) probably leads to higher intradialytic hypotension compared with neutral dialysate [Na+] (138 to 140 mM) (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).